BIND Biosciences, a clinical-stage biopharmaceutical company, has releases promising data from an ongoing phase I study of BIND-014, the company’s lead drug candidate within a new class of targeted therapeutics, Accurins, that are programmed to concentrate at tumors.
The preliminary phase I data demonstrated safety and tolerability of BIND-104, as well as evidence of anti-tumor activity with six of 17 patients with advanced or metastatic solid tumor cancers. In addition, BIND-014 demonstrated evidence of anti-tumor activity in tumors for which conventional docetaxel is known to have minimal activity.
BIND-014 represents the first targeted and programmable Accurin nanomedicine to reach the clinic from BIND's proprietary drug development platform that creates targeted therapeutics designed to accumulate at the site of disease for high drug concentration and maximum therapeutic effect. BIND-014 employs a combination of a targeted biodegradable nanoparticle and docetaxel, a proven cancer drug. The ongoing phase I study has reached a dose of 75mg/m2, with dose escalation and tolerability continuing.
"The early clinical activity observed with BIND-014 in patients with advanced or metastatic solid tumor cancers is encouraging. There is a critical need for targeted treatment options for patients with difficult to treat solid tumors and we look forward to further evaluating the potential of BIND-014," said Daniel D. Von Hoff, M.D., F.A.C.P., principal investigator for the study.
BIND Bioscience hopes to advance to phase II development later this year.
